TCGA-62-A46P-01A-11R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.260
- COAGULATION+0.180
- KRAS_SIGNALING_DN+0.170
- ANGIOGENESIS+0.160
- PANCREAS_BETA_CELLS+0.150
- FATTY_ACID_METABOLISM+0.140
- BILE_ACID_METABOLISM+0.120
- XENOBIOTIC_METABOLISM+0.110
- ADIPOGENESIS+0.100
- ESTROGEN_RESPONSE_LATE+0.090
Top 10 suppressed
- G2M_CHECKPOINT-0.640
- E2F_TARGETS-0.630
- MITOTIC_SPINDLE-0.540
- MYC_TARGETS_V1-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYC_TARGETS_V2-0.400
- MTORC1_SIGNALING-0.350
- PI3K_AKT_MTOR_SIGNALING-0.340
- UV_RESPONSE_DN-0.340
- APICAL_SURFACE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3d1f44d8-6084-47cb-b57b-099f2cd1fa0e | — | — | 0.894 |
| 2 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.891 |
| 3 | TCGA-49-4510-01A-01R-1206-07 | — | cohortA2 | 0.876 |
| 4 | TCGA-62-A470-01A-11R-A24H-07 | — | cohortA3 | 0.869 |
| 5 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.865 |
| 6 | s0094283 | — | — | 0.843 |
| 7 | 4e64826b-fffb-4430-bc34-ea6086e89a0a | — | — | 0.828 |
| 8 | SRR12202450 | — | — | 0.826 |
| 9 | TCGA-GM-A3NY-01A-11R-A21T-07 | — | B | 0.825 |
| 10 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |